Hybrid Events

Spotlight on Immuno-Oncology

August 01, 2023 | 10:00 AM CT

The Spotlight on Immuno-Oncology conference will feature speakers touching on a variety of topics including, but not limited to, novel CAR designs and approaches beyond B-Cell malignancies, genome and epigenome editing, and direct in vivo delivery for cancer immunotherapy. This program aims to transcend the basics of cell therapy and CAR T cells and dig deeper into gene engineering and the intersection of gene and cell therapy in this space. We believe this program will spark new conversations and breakthroughs in immuno-oncology.

Abstract submission open through Friday, June 2, at 11:59 p.m. (PT)!

If you're conducting research related to any of the topics below, send us your abstract today:

  • Novel CAR Designs and Approaches

  • B-Cell Malignancies and Beyond

  • TCR-Based Cancer Immunotherapy

  • Beyond T Cells

  • Genome and Epigenome Editing

  • Direct In Vivo Delivery for Cancer Immunotherapy

Submit your abstract

NOTE: The agenda for this event is in development. Updates will be made to this page as speakers are confirmed.

Tuesday, August 1

B-Cell Malignancies and Beyond

Mike Jensen, MD
Seattle Children's Research Institute
Manufacturing Process Modulates CAR T Cell Efficacy and Fitness in Pediatric Subjects

Carl June, MD
University of Pennsylvania
CAR T Cell Clinical Trials

Rayne Rouce, MD
Baylor College of Medicine
CAR T for T-Cell Malignancies


Chiara Bonini, MD
Vita-Salute San Raffaele University
TCR and Inhibitory Receptor Genome Editing

Aude Chapuis, MD
Fred Hutchinson Cancer Research Center

Chris Klebanoff, MD
Memorial Sloan Kettering Cancer Center

Dirk Busch, MD
Technical University of Munich

Direct In Vivo Delivery

Saar Gill, MBBS, PhD, FRACP
University of Pennsylvania
CAR T Cell Targeting In Vivo

Wednesday, August 2

Genome and Epigenome Editing for Cancer Immunotherapy 

Pietro Genovese, PhD
Harvard Medical School
Clonal Tracking of Gene Edited Cells

Justin Eyquem, PhD
Novel AAV Variants Enabling Gene Targeting for Experimental T Cell Immunology

Jamie Schafer, PhD
Chroma Medicine
Using Epigenetic Editing to Engineer CAR T Cells

Beyond T Cells

Paula Cannon, PhD
University of Southern California

Bob Valamehr, PhD
Fate Therapeutics, Inc.
IPSC-Derived Cells

Michael Hudecek, MD
University Hospital Wurzburg
Minicircles & Transposon for T Cell Production

Catherine Bollard, MD
The George Washington University
Native T-Cells for Adoptive Cell Therapy

Support the Conference

Download the prospectus below and contact development@asgct.org if you're interested in learning more about how your company can support this event.




Policy Summit

Sept. 18-19 | Washington, DC

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.